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Background
Transfusion is a cornerstone of the management of sickle cell disease but carries a high risk of
hemolytic transfusion reaction, probably because of differences in erythrocyte antigens
between blood donors of European descent and patients of African descent. Patients may expe-
rience hemolytic transfusion reactions that are delayed by from a few days to two weeks and
manifest as acute hemolysis (hemoglobinuria, jaundice, and pallor), symptoms suggesting
severe vaso-occlusive crisis (pain, fever, and acute chest syndrome), and profound anemia,
often with reticulocytopenia. This case-series study aims to describe the main characteristics of
this syndrome, to discuss its pathophysiology, and to propose a management strategy. 
Design and Methods
We identified 8 pediatric cases of delayed hemolytic transfusion reactions between 2006 and
2009 in the database of the Necker Hospital, France. All patients had received cross-matched
red cell units compatible in the ABO, RH, and KEL systems. We reviewed the medical charts
in the computerized blood transfusion databases. All patients were admitted to the intensive
care unit. We progressively adopted the following strategy: intravenous immunoglobulins, and
darbopoietin alpha when the reticulocyte count was below 150¥109/L, without further blood
transfusion during the acute episode unless absolutely necessary.  
Results
The median time between the transfusion and the diagnosis of delayed hemolytic transfusion
reaction was six days. All patients had severe bone pain; all but one had a high-grade fever. Five
patients had hemoglobin levels less than than 4g/dL and 3 had reticulocytopenia.  In 5 patients,
no new antibody was found; one patient had weakly reactive antibodies. Only 2 patients had
new allo-antibodies possibly responsible for the delayed hemolytic reaction.  
Conclusions
The initial symptoms of delayed hemolytic transfusion reaction were complex and mimicked
other complications of sickle cell disease. In most of our cases, no new antibody was identified,
which underlines the complexity of the pathophysiology of this syndrome. 
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rituximab.
Citation: de Montalembert M, Dumont M-D, Heilbronner C, Brousse V, Charrara O, Pellegrino B,
Piguet C, Soussan V, Noizat-Pirenne F. Delayed hemolytic transfusion reaction in children with sickle
cell disease. Haematologica 2011;96(6):801-807.  doi:10.3324/haematol.2010.038307
©2011 Ferrata Storti Foundation. This is an open-access paper. 
ABSTRACT
haematologica | 2011; 96(6)
ORIGINAL ARTICLES
801
Introduction
Blood transfusion is a cornerstone of the management of
sickle cell disease (SCD).1,2 The goals of blood transfusion
are to increase oxygen distribution to the tissues and/or to
replace the rigid sickle-shaped red blood cells (RBCs) by
deformable RBCs. However, blood transfusion in patients
affected with SCD is associated with a high rate of
hemolytic transfusion reactions. The differences in RBC
antigens between blood donors of European descent and
patients with SCD of Afro-Caribbean descent often result
in allo-immunization. Antigenic differences are found
within common variants and within variant antigens.3,4
Some partial antigens are found exclusively in the Afro-
Caribbean population, and carriers of these variant anti-
gens can produce allo-antibodies when exposed to the
complete antigen. These antibodies can cause severe
delayed hemolytic transfusion reactions (DHTRs), which
present specific features in SCD patients.5-9 DHTR has
been reported to occur in 4-11% of SCD patients given
blood transfusions.6,10-12 DHTRs occur from a few days to
two weeks after a blood transfusion and manifest as clin-
ical features of acute hemolysis (hemoglobinuria, jaundice,
and pallor) combined with symptoms suggesting severe
vaso-occlusive crisis (pain, fever, and sometimes acute
chest syndrome). The destruction of both the donor’s and
the recipient’s RBCs leads to an abrupt drop in the hemo-
globin level, to a value lower than the pre-transfusion
value. Reticulocytopenia is common. Screening tests may
show allo-antibody reactivation, sometimes with clinical-
ly relevant auto-antibodies.13 However, cases with no
detectable antibody are not infrequent. Corticosteroid
and/or intravenous immunoglobulin (IVIg) therapy has
been reported to ensure recovery from DHTR.5-9,13,14 More
recently, two studies reported the use of rituximab for pre-
venting DHTR.13,15 The pathophysiology of this syndrome
remains unclear, especially when there is no detectable
antibody. A recent study suggests accelerated apoptosis of
donor RBCs.12
This article describes a series of patients with SCD and
DHTR in order to underline several important points.
First, our cases illustrate the complexity of the initial clin-
ical picture in DHTR, which mimics other complications
of SCD, leading to a risk of misdiagnosis. Further blood
transfusions given to treat a mistakenly diagnosed SCD
complication can cause a life-threatening exacerbation of
the hemolysis. Second, many of our patients had no
detectable antibody. Finally, we describe the treatments
used for our patients and we suggest a management strat-
egy. 
Design and Methods
Patients
We identified 8 pediatric patients (5 girls and 3 boys) with SCD
and DHTR in the Necker Hospital database. DHTR was defined
as the abrupt onset, at least three days after an RBC transfusion,
of signs indicating accelerated hemolysis: hemoglobinuria, jaun-
dice, pallor, hemoglobin (Hb) level drop, lactic dehydrogenase
(LDH) elevation, and bilirubin elevation above the baseline value.
In patients with more than one DHTR, the index episode was the
most recent one. All 8 patients had homozygous SCD (SS dis-
ease); 7 were from Africa and one from the Caribbean. Median
age was 10.5 years (range 2-15 years). Of these 8 patients, 2 were
receiving follow up for SCD at the Necker Hospital before the
DHTR, 4 were transferred to the intensive care unit of the Necker
Hospital for management of the DHTR, and 2 were managed at
their usual reference center (Poissy-Saint Germain en Laye
Hospital and Limoges Hospital, respectively) according to the
protocol suggested by the Necker Hospital. All DHTRs occurred
between 2006 and 2010. 
All 8 patients received cross-matched RBC units compatible in
the ABO, RH, and KEL systems. Patients with positive screening
tests received units extensively matched for the other immuno-
genic blood groups (JK, FY, and MNS). When DHTR was suspect-
ed, a new screening test, a direct antiglobulin test (DAT), and an
elution test were performed. Finally, so far, molecular analysis
has been performed in two settings: patients with Rh antibodies
against expressed Rh antigens to detect Rh variants prone to allo-
immunization, thereby distinguishing between allo- and auto-
antibodies; and in patients with depressed expression of Rh anti-
gens.
Methods
We retrospectively reviewed the medical charts of the 8
patients. Further information on their transfusion history was
obtained from the computerized blood transfusion databanks for
the Paris area (where the Necker, Ambroise Paré, Trousseau, Le
Chesnay, and Poissy-St Germain en Laye Hospitals are located)
and for the Aquitaine Limousin area (where the Limoges Hospital
is located). We recorded the number of previous transfusions, any
past history of erythrocyte allo-immunization and/or DHTR, and
reasons for the transfusion responsible for the current DHTR
(Table 1 and Figure 1). We may have underestimated the number
of previous transfusions, as some patients may have received
blood transfusions outside the Paris or Aquitaine Limousin areas
that were not recorded in their medical charts, although this
seems highly unlikely. The patients are numbered according to
the chronological order of DHTR diagnosis. We performed
molecular analysis in patients 4, 6, and 8 who exhibited previous
(patient 4) or new (patients 6 and 8) allo-antibodies; and in
patient 3 who had decreased expression of the RH antigen.
Results are shown in Table 2.
We had no standardized protocol for managing DHTR from
2006 to the beginning of 2009 (patients 1, 2 and 3). We progres-
sively adopted the following strategy: the child is transferred to
the intensive care unit and given oxygen, fluids, and analgesics;
1g/kg intravenous immunoglobulins are infused, and if needed,
immunoglobulin infusion is repeated on the following day; if the
reticulocyte count is less than 150¥109/L, darbopoietin alpha 5
mg/kg is administered. Most importantly, further blood transfu-
sions are avoided during the DHTR. After the DHTR is resolved,
hydroxyurea therapy is considered to minimize transfusion
requirements. 
Results
Clinical presentation 
The main clinical and laboratory findings (except the
immuno-hematologic data) are reported in Table 1. The
main past immuno-hematologic data are reported in Table
2 and Figure 1. The median time from the last transfusion
to the diagnosis of DHTR was six days (range 3-15). All
children had severe bone pain and all but one had a high-
grade fever. The 7 febrile children had blood cultures per-
formed, with negative results.  In 3 patients, severe bone
pain with a fever and C-reactive protein elevation to more
than 300 mg/L led to an initial diagnosis of osteomyelitis
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(patients 1, 4 and 5); of these 3 patients, one underwent a
bone aspiration which showed no organisms. In 5 patients
(patients 3, 4, 5, 6 and 7), the combination of a fever, chest
pain, hypoxemia, and a new pulmonary infiltrate led to a
diagnosis of acute chest syndrome. In 2 patients (patients
1 and 5), renal infarction was suspected then ruled out by
ultrasonography of the kidneys. The median Hb level at
diagnosis was 5.65 g/dL (range 3.7-8.6 g/dL). The median
fall in Hb from the post-transfusion value was 3.85 g/dL
(range 2-5.1 g/dL). Reticulocyte counts were decreased
(≤100¥109/L) in 4 patients, unchanged in 3 patients, and
not determined in one patient. In all patients who had
LDH and bilirubin assays, the values were increased com-
pared to baseline. Serum sodium was low in all patients
(mean 129±4.4 mmol/L; normal range for the laboratory
136-146 mmol/L). In the 3 patients who had their urinary
sodium measured, the values were excessively high given
the low serum sodium levels. Renal function was tem-
porarily impaired in one patient (#6) who had an increase
in creatinine level to 155 mmol/L (normal range for the lab-
oratory 20-75 mmol/L) with a concomitant b2-microglob-
ulin value of 10 mg/mL (normal range for the laboratory 0-
0.35 mg/mL). This renal function impairment with tubu-
lopathy resolved within five days.
History of delayed hemolytic transfusion reaction 
Patients 1, 2, 3, and 7 had no prior history of DHTR and
their pre-transfusion screening tests were negative. Their
transfusions were cross-match compatible. The screening
tests and DATs remained negative during the DHTR. No
antibodies against RBCs were detected at a distance from
the DHTR episode (data not shown). 
Patient 4 had had two previous DHTRs. The first
episode occurred in 2003 and was due to the production
of anti-M antibody. A blood transfusion in 2004 was
uneventful. In 2007, she again received a blood transfusion
after which she experienced a DHTR due to anti-C anti-
body. Tests performed before the 2009 transfusion that
caused the last DHTR were negative for anti-M and anti-
C antibodies. She was given cross-match-compatible
blood units negative for C, E, K, Fya, M, and S. Screening
tests performed after the DHTR were negative. She had an
RN variant allele, producing a partial C antigen. Blood
group evaluation in the RH system showed no decrease in
the expression of this variant antigen. Patient 5 had a
serum anti-M antibody before the transfusion and
received M-negative cross-matched units. After onset of
the DHTR, only weak reactions were evidenced, with no
detectable specificity. The DAT was negative. Patient 6
had no prior history of DHTR but had a weakly reactive
screening test with no detectable specificity. The RH phe-
notype was normal. The post-DHTR screening test
showed anti-D and anti-S antibodies, and the DAT was
IgG-positive. This patient had received D+, S+ RBC units.
In this case, anti-S and anti-D antibody production could
be the cause of the DHTR. Molecular analysis showed a
partial D antigen (DAR variant). Finally, patient 8 had had
a DHTR in 2008. Her phenotype was D+C-E-c+e+, K-,
Fya-Fyb-, S-s+, Lea-Leb-. The DHTR in 2008 occurred
after a transfusion of 5 units, one of which was Leb+ and
another S+. All units were D-, E- , C-, and Fya-. The only
antibody detected after the DHTR was anti-Leb. In 2010,
before a tonsillectomy, she received 3 units including two
Fya+, Fyb+ units and one D+ unit.  She developed new
antibodies (anti-D, anti-C, anti-e, anti-Fy3, and anti-Kpa)
during this second DHTR episode. Molecular analysis
showed weak D type 4, which could be considered a par-
tial D antigen. 
Treatments and outcomes (Table 3)
The first 3 patients experienced DHTRs in 2006, when
we had no standardized protocol for managing DHTRs in
SCD patients. Given that the minimal Hb levels were not
very low (4.5 to 5.9 g/dL), no specific treatment was given.
Delayed hemolytic reaction in SCD children
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Table 1. Clinical and laboratory characteristics of the delayed hemolytic transfusion reactions
Patient Reason Time from ACS Post- Hb at Lowest Retic. LDHa Bili- CRP Serum
number, For Tx RBC Tx to Tx drop diagnosis Hb count (IU/L) -rubinb (mg/L) sodiumc
gender, onset in Hb of DHTR (g/dL) (x109/L) mmol/L (mmol/L)
age (yrs) (days) (g/dL) (g/dL)
1, M, Before 3 No 3.7 5.9 5.9 100 ND ND 300 120
14 trip to
Africa
2, M, Fever 4 No 5.1 5.4 5.4 ND ND 54 ND 134
2
3, M, VOC 6 Yes 2.2 6.7 4.5 212 1872 ND 327 130
4
4, F, Before 7 Yes 5 7 1.9 100 4313 142 357 129
15 surgery
5, F, Abnormal 6 Yes ND 4.4 3.5 86 3172 76 369 128
10 TCD
6, F, Before 15 Yes ND 4.8 3.6 278 ND 53 44 132
14 surgery
7, F, VOC 6 Yes 2 3.7 3.2 237 ND 53 243 130
11
8, F, Before 6 No 4 8.6 3.6 36 3657 118 131 134
9 surgery
DHTR: delayed hemolytic transfusion reaction; Tx: transfusion; TCD: transcranial Doppler; VOC: vaso-occlusive crisis; RBC: red blood cell; ACS: acute chest syndrome; Hb: hemoglobin;
Retic.: reticulocyte; LDH: lactic dehydrogenase; CRP: C-reactive protein;  anormal range for the laboratory, 215-460 IU/L; bnormal range for the laboratory, 0-17 µmol/L; cnormal range
for the laboratory, 136-146 mmol/L.
A spontaneous favourable outcome was seen in all 3
patients. The next 5 cases occurred in 2009 and 2010.
Diagnosis was rapid, and the Hb levels at diagnosis ranged
from 3.7 to 8.6 g/dL. Treatment for DHTR was started
immediately and consisted of corticosteroids in one
patient (patient 6), IVIg in 3 patients (patients 4, 5 and 7),
and both in one patient (patient 8). Three patients
(patients 4, 5 and 8) had reticulocytopenia (100¥109/L,
86¥109/L, and 36¥109/L) and received erythropoietin. Hb
levels continued to decrease in 6 patients in the days fol-
lowing diagnosis and reached a median minimum value of
3.60 g/dL (1.9-5.9) after a median of two days (range 1-5).
In patient 4, the Hb level plateaued at about 4 g/dL before
dropping abruptly to 1.9 g/dL. Usually, the drop in Hb
level stopped one day after the end of the clinical hemo-
globinuria. A further transfusion was considered indispen-
sable in patients 4 and 5, whose Hb levels just before the
repeat transfusion were 1.9 g/dL and 3.5 g/dL, respective-
ly. Both patients received IVIg before the new transfusion
which was well tolerated with no further hemolytic reac-
tion.
The patients who had a fever received intravenous cefo-
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Table 2. Immuno-hematologic characteristics of the 8 study patients.
Patients Previous known Pre-transfusion Post-DHTR Post-DHTR DAT Post-DHTR Blood molecular 
antibodies screening test screening test elution typing
1 0 0 0 negative negative not done
2 0 0 0 negative not done not done
3 0 0 0 negative not done Partial C:RN/ce(667)
4 Anti-C, anti-M 0 0 negative not done Partial C:RN/ce
5 Anti-M Anti-M + weak non-specific Anti-M + weak non-specific negative negative not done
6 Weak non-specific weak non-specific Anti-D, anti-S positive positive Partial D:DAR
7 0 0 0 negative negative not done
8 Anti-Leb, weak non-specific Anti-Leb Anti-D, anti-C, anti-e, Positive: IgG negative Partial D: weak D type 4
anti-Leb, anti-Fy3, anti-Kpa
In bold: new allo-antibodies evidenced after the DHTR episode; DHTR: delayed hemolytic reaction; DAT: direct antiglobulin test.
Table 3. Treatments and outcomes.
Patient Corticosteroids Intravenous Erythropoietin Subsequent 
immunoglobulins hydroxyurea 
treatment
1 0 0 0 yes
2 0 0 0 yes
3 0 0 0 yes
4 0 0.5 g/kg x 2 darbopoieitin yes
alpha
300 µg x 2
5 0 1 g/kg x 2 darbopoietin yes
alpha 
150 µg x 2
6 1 mg/kg/d IV 0 0 no
10 days
7 0 1 g/kg 0 no
8 2mg/kg 1 g/kg epoetin beta yes
2 days days 1,2,8,9 50 IU/Kg x 3/week
2 weeks
Figure 1. Transfusion and immuno-hematologic findings.
taxime (n=6) or ceftriaxone (n=1). The antibiotics were
always started after the onset of hemoglobinuria. The 3
patients with suspected osteomyelitis received intra-
venous rifampin combined with a 3rd generation
cephalosporin, started after the diagnosis of DHTR.
Patients with suspected ACS were managed with
macrolides and non-invasive ventilation. 
Hydroxyurea was started just after the DHTR in 4 of the
8 patients (patients 3, 4, 5 and 8) in the hope of decreasing
transfusion requirements. In 2 additional patients (patients
1 and 2), hydroxyurea was started later because of recur-
rent painful crises. The appropriateness of hydroxyurea
therapy in the remaining 2 patients is still under debate.
Of the 8 patients, only one (patient 2) has received further
blood transfusions since the index DHTR episode, in
2006. The transfusions were given for pulmonary compli-
cations and followed by hydroxyurea therapy: these were
well tolerated. The patient died suddenly in 2010 during
hospitalization for a moderate painful crisis treated with
intravenous hydration and paracetamol, with no transfu-
sion. No autopsy was performed and the cause of death
was not determined.
Discussion
We studied 8 children with SCD who experienced
DHTRs, including 5 with Hb levels less than 4 g/dL. These
cases illustrate the need for routinely considering DHTR in
SCD patients whose clinical and laboratory signs of
hemolysis suddenly worsen within two weeks of a blood
transfusion. Hemoglobinuria is strongly suggestive of
DHTR in SCD. DHTR can occur even after transfusions
that were matched at least in the ABO, RH, and KEL sys-
tems and that produced a negative serological cross-match
test. Negative immunological tests do not exclude a
DHTR. The increase in HbS percentages indicating
destruction of the transfused RBCs confirms the diagnosis
of DHTR. In most of our patients, DHTR was not suspect-
ed initially: the diagnosis initially considered most likely
was osteomyelitis in 3 patients and renal infarction in 2
patients. Maintaining a high index of suspicion for DHTR
is crucial as mistakenly diagnosing another complication
(e.g. osteomyelitis or ACS) may lead to a further transfu-
sion which may exacerbate the hemolysis. Tubulopathy
related to intravascular hemolysis is extremely common in
DHTR, as shown by the presence of hyponatremia in all
our patients, with transient renal failure in one patient.
A limitation of our study is that we cannot assess the
occurrence rate of DHTR in the pediatric population given
the retrospective study design and our status as a reference
center that serves not only our area but also patients
referred to us from other areas. To determine the occur-
rence rate of DHTR, and to gather additional information
on the spectrum of clinical and laboratory presentations,
we are planning a one year prospective study in the Paris
area which will be conducted both by the reference cen-
ters for SCD and by the French blood transfusion service.
The pathophysiology of DHTR in SCD patients is
unclear. Classically, DHTR is ascribed to a reaction
between anti-RBC antibodies produced by the recipient
and antigens expressed by the donor RBCs. However,
anti-RBC antibodies are often undetectable in SCD
patients with DHTR.5 Of our 8 patients, 5 (patients 1, 2, 3,
4 and 7) had no detectable new antibodies. Patient 5 had
weakly reactive antibodies. Only in 2 patients (patients 6
and 8) were we able to ascribe the DHTR to transfusion-
induced reactivation of allo-antibody production. Thus, in
three-quarters of our patients the routine immuno-hema-
tologic tests failed to identify the cause of the DHTR. Of
the 5 patients with no detectable antibodies, all but
patients 4 and 8 had no prior history of DHTR despite
having had several previous transfusions. In this situation,
the clinical and laboratory status at the time of transfusion
may influence the outcome of the transfusion, independ-
ently of the allo-immunization process. According to one
hypothesis, stored donor RBCs may experience accelerat-
ed eryptosis in the bloodstream of SCD patients, with
externalization of the phosphatidylserine membrane at
the outer surface of the cell.12,16 Eryptosis may be the first
step in a cascade of events which together cause accelerat-
ed RBC destruction and hemolysis. RBCs may be rapidly
destroyed by macrophages, which are probably activated.
Another possibility is that inflammatory enzymes, such as
phospholipase A2, hydrolyze the senescent phos-
phatidylserine-exposing RBCs.17 DHTR may result from a
combination of several factors18 and the role of concomi-
tant inflammation is under debate. SCD has been postu-
lated to be a chronic inflammatory disease.19 In our patient
1, the transfusion was planned before a trip to Africa in
the absence of any identifiable inflammatory risk factors.
In patients 4 and 6, however, the transfusion was given
before a surgical procedure. Conceivably, cytokine pro-
duction during surgery may have led to an inflammatory
reaction in these patients.20 Patient 4 received several
transfusions between 2003 and 2009, and 2 of the 3 trans-
fusions followed by DHTRs were given before a surgical
procedure (tonsillectomy in 2003 and cholecystectomy in
2009). In patient 5, the pre-transfusion screening test
showed only weak non-specific reactivity. One possibility
is that a non-clinically significant antibody may become
significant when the donor RBCs undergo accelerated
senescence in the bloodstream. Patients 6 and 8 had allo-
antibodies that can be considered responsible for the
DHTR. In patient 6, a common anti-S antibody and an
uncommon anti-D antibody were detected. The develop-
ment of anti-S antibody could not be prevented because of
the shortage in France of donors of African descent having
the same extended phenotype as SCD patients. The anti-
D antibody was probably present before the transfusion
but not detected because of its weak reactivity. This anti-
D antibody was related to the presence of a partial D anti-
gen of the DAR type in this patient. Similarly, no strictly
antigen-identical units were available for patient 8, in
whom the production of anti-Fy3 could not be prevented.
Although the units were C-negative, anti-C antibodies
developed, via a mechanism that remains unclear.  This
patient also developed anti-e antibodies, although her
phenotype was e+. Molecular typing of the RHCE found
no variant, making an auto-anti-e the most probable
hypothesis. On the contrary, the presence of anti-D anti-
body can be ascribed to the partial D antigen identified by
molecular typing. However, this anti-D antibody was pro-
duced after a single D-positive transfusion.  
Finally, the risk factors for DHTR in patients without
detectable antibodies are unknown. Consequently,
patients at risk for a first or recurrent episode of DHTR
cannot be identified. 
The uncertainties about the pathophysiology of DHTR
in SCD patients complicate the identification of the best
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treatment approach. Previously described patients usually
received corticosteroid therapy,6,7,14 IVIg,8 or both.5,9,21 The
protocol currently used at our institution involves IVIg
infusion. However, no randomized controlled trials have
been carried out to assess treatments for SCD patients
with DHTR. All previous publications insist on the impor-
tance of avoiding further RBC transfusions. We minimize
the use of corticosteroids, which can induce severe side
effects in children with SCD.22 Reversible posterior
leukoencephalopathy syndrome was recently reported
after corticosteroid therapy in a child with SCD and
DHTR.14 Given the observational nature of our study, no
conclusions can be drawn about the efficacy of IVIg ther-
apy. Nevertheless, the 4 patients who received IVIg thera-
py (0.5-1 g/kg, 1-4 injections) experienced resolution of
the hemolytic process and tolerated the infusions well.
The effectiveness of IVIg therapy in patients 4 and 7, who
had no pre-existing antibodies or new antibodies detected,
does not rule out accelerated RBC senescence. Although
competitive mononuclear phagocytic system blockade is
among the most widely accepted mechanisms for explain-
ing the therapeutic effects of IVIg therapy in patients with
detectable antibodies, other mechanisms may be involved
in patients without detectable antibodies. Thus, IVIg ther-
apy affects the cellular immune response: for instance,
IVIg therapy alters the apoptosis of lymphocytes and
monocytes via a Fas (CD95)-dependent effect that is prob-
ably due to naturally occurring anti-Fas antibodies con-
tained in IVIg and capable of blocking Fas-FasL binding.23
Thus, IVIg therapy may act by diminishing the destruction
by macrophages of donor RBCs undergoing accelerated
senescence. Another possible effect of IVIg therapy is
cytokine modulation. IVIg therapy induces the production
of interleukin-1 receptor antagonist, which can inhibit
inflammation and macrophage phagocytic function.24,25
Erythropoietin-stimulating agents were given to the 3
patients with reticulocytopenia because we could not pre-
dict the duration of this manifestation; its mechanism is
unknown. 
Finally, the indications for rituximab therapy in SCD
patients with DHTR remain unclear. Rituximab was used
preventively in a poly-immunized 33-year old SCD
patient who had had a history of DHTR two years earlier
with a positive DAT and who required another transfu-
sion in preparation for hip surgery. Rituximab was given
before and after this transfusion, which was well tolerat-
ed.13 Rituximab combined with corticosteroid therapy and
darbopoietin alpha was used in a 30-year old SCD patient
with DHTR, previously known anti-MNS antibodies, and
newly detected anti-Leb antibodies.15 New antibodies to
RBCs were detectable in both these patients. Of our 8
patients, only 2 had detectable anti-RBC antibodies. They
may be candidates for rituximab therapy should further
blood transfusions prove to be unavoidable in the future. 
Whether molecular analysis should be performed rou-
tinely in SCD patients merits discussion. Of our 8 patients,
4 underwent molecular analysis, which consistently
showed a variant RH antigen. Patient 6 had a partial D,
type DAR, and an anti-D antibody was considered
responsible for the DHTR. In patient 4, a partial C variant
had caused a prior DHTR, although the associated anti-C
antibody was not involved in the index DHTR. A previous
study showed that the C antigen should always be evalu-
ated for a partial variant in SCD patients.11 In patient 3, a
complex combination of rare alleles was found but was
not involved in the index DHTR. Finally, patient 8, who
had a weak D type 4, developed anti-D antibodies after
receiving a single D+ unit. All previous transfusions in this
patient were D-negative. It is important to point out that,
in patients with variants, serological blood-group determi-
nation showed no evidence of depressed expression. This
finding suggests that molecular analysis may be warranted
in all patients and not only in those with altered serologi-
cal phenotypes. This issue is currently under review at our
institution.
In conclusion, we believe that DHTR may be underesti-
mated in SCD patients as the manifestations mimic other
complications of SCD and post-transfusion screening tests
are usually negative. Patients in whom the diagnosis of
DHTR is missed may receive repeat transfusions, which
may contribute to the mortality associated with SCD. The
high proportion of DHTR cases without identifiable anti-
bodies suggests that multiple factors are involved in the
pathophysiology of this life-threatening complication.
Among these factors, inflammation may play a substantial
role. 
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